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Notch signaling is a highly evolution­
arily conserved pathway implicated in   
diverse functions during embryogene­
sis and in self­renewing tissues of the 
adult organism. These functions include 
the maintenance of stem cells, cell fate 
specification, proliferation, and apop­
tosis (Artavanis­Tsakonas, 1988; Leong 
and Karsan, 2006). In mammals, there 
are four Notch receptors (Notch1­4), 
three Delta­like ligands (Dll1, Dll3, and 
Dll4), and two ligands of the Jagged fam­
ily (Jag1 and Jag2). When membrane­ 
bound  receptors  interact  with  cognate 
ligands on an adjacent cell, two con­
secutive  proteolytic  cleavages  of  the   
receptor are initiated, freeing the intra­
cellular portion of Notch to enter the 
nucleus  and  activate  the  transcrip­
tion of target genes. The first cleavage 
(S2) in the heterodimerization domain 
(HD) by ADAM10 (A disintegrin and   
metalloprotease 10) generates the sub­
strate  for  the  second  cleavage  (S3)   
by the ­secretase complex. Canonical 
Notch signaling requires the forma­
tion of a complex with a transcription 
factor of the CSL (CBF­1/Su(H)/Lag­1)   
family, CBF­1/RBP­Jk/KBF2 in mam­
mals. CBF­1 binds DNA in a sequence­ 
specific manner and acts as a repressor of 
transcription in the absence of Notch   
signaling. Displacement of co­repressors 
bound to CBF­1 by intracellular Notch 
(ICN) allows the recruitment of co­ 
activators, such as MamL1 (Mastermind 
Like­1), and histone acetyltransferases, 
such as p300, to create a short­lived tran­
scriptional activation complex. Recent   
genome­wide chromatin immunopre­
cipitation arrays and sequencing have 
identified a large number of genes that 
can  be  regulated  directly  by  Notch 
(Palomero et al., 2006; Hamidi et al., 
2011). Many of these target genes may 
be cell type specific, but there are a few 
well  characterized  transcriptional  tar­
gets of ICN­CBF1, including the HES  
(hairy enhancer of split) family of tran­
scription factors, Notch­related ankryin 
repeat protein (NRARP), c-MYC, and 
DTX1 (Deltex1; Weng et al., 2006).
Notch as an oncogene
The first evidence for the involvement 
of Notch signaling in cancer came from 
T­ALL. T­ALL is a neoplastic disorder 
accounting  for  10–20%  of  all  acute 
lymphoblastic leukemias. In 1991, Ellisen   
et al. (1991) identified a t(7;9)(q34;q34.4) 
translocation in T­ALL patients, which 
resulted in fusion of the 3 region of 
NOTCH1  into  the  TCR  locus  and 
consequent overexpression of the ac­
tive form of Notch1 (ICN1). This trans­
location appeared to be rare, found in 
<1% of T­ALL cases. However, 13 yr 
later, Weng et al. (2004) identified ac­
tivating NOTCH1 mutations in 56% 
of T­ALL cases examined, introducing 
NOTCH1 mutation as the main onco­
genic lesion in T­ALL. Two major hot­
spots of mutations were characterized: 
mutations in the HD domain that induce   
ligand­independent activation, and mu­
tations in the PEST (proline­glutamate­ 
serine­threonine­rich)  carboxy­terminal 
domain that increase stability of ICN1 
(Thompson et al., 2007). Additionally, 
inactivating mutations were identified in   
FBW7, an E3 ubiquitin ligase responsi­
ble for ICN1 degradation and subse­
quent  termination  of  Notch  signaling 
(Malyukova et al., 2007; Maser et al., 
2007; O’Neil et al., 2007; Thompson   
et al., 2007). Of note, animal modeling 
suggested  that  NOTCH1  mutations 
(HD or PEST) are either insufficient   
to induce disease or are very weak onco­
genes in T­ALL, even when they are 
overexpressed (Chiang et al., 2008). We 
recently generated knockin mice carry­
ing  human  NOTCH1  mutant  alleles, 
and our studies also indicated that none 
of these mutations are sufficient to in­
duce disease (unpublished data).
After the discovery of its involve­
ment in T­ALL, Notch signaling was 
also implicated in various solid tumors, 
including  breast  cancer,  medulloblas­
toma,  colorectal  cancer,  non–small  cell 
lung carcinoma (NSCLC), and melanoma 
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adult progenitor cells are the tumor­
initiating cells of HCC after RB inacti­
vation. In corroboration with previous 
findings  showing  that  hyperactivation   
of E2F and Myc signals are sufficient to 
induce HCC, both pathways were up­
regulated in the TKO mice.
Using whole transcriptome profil­
ing  and  gene  set  enrichment  analysis, 
Viatour  et  al.  (2011)  showed  that  the 
Notch  pathway  was  also  up­regulated 
in TKO mice, suggesting an oncogenic 
role for Notch signaling in HCC de­
velopment. Unexpectedly, inhibition of   
Notch  signaling  in TKO  mice  using 
DAPT,  a  potent  ­secretase  inhibitor, 
led  to  accelerated  HCC  development. 
And enforced activation of Notch sig­
naling using ICN1 led to cell cycle ar­
rest and apoptosis in primary HCC cells 
isolated from TKO mice, as well as in   
human HCC cell lines. To further ad­
dress the clinical relevance of these ob­
servations, the authors looked at Notch 
activation status in a cohort of patients. 
They found that  patients  with  better   
survival showed significantly higher ex­
pression of Notch­related genes, includ­
ing  HES1. Taken  together,  these  data   
strongly support a potential tumor sup­
pressor role for Notch signaling in HCC.
Our laboratory has recently found 
that  conditional  Notch  loss­of­function 
through  the  deletion  of  Nicastrin   
(NCSTN),  an  essential  component  of 
the ­secretase complex, or compound 
deletion of NOTCH1 and NOTCH2, 
resulted  in  a  myeloproliferative  syn­
drome with common features of the 
human  disease  chronic  myelomono­
cytic leukemia (CMML; Klinakis et al., 
2011). Whole transcriptome analysis   
revealed that Notch signaling inhibited 
a monocytic/granulocytic differentiation 
program in an early multipotential pro­
genitor. This was at least partially medi­
ated by direct repression of the PU.1 and 
C/EBP promoters by HES1. Sequenc­
ing  of  Notch  pathway  genes  revealed 
that  12%  of  CMML  patients  har­
bored inactivating mutations in NCSTN, 
MAML1), APH1A, or NOTCH2. These 
mutations were unique to CMML and 
were not found in other myeloprolif­
erative disorders such as Polycythemia 
vera  and  myelofibrosis. Analogous  to 
the same pathway may have growth­ 
suppressive functions in other hematopoi­
etic cells, skin, and pancreatic epithelium, 
as well as in hepatocytes.
In  the  skin,  Notch  receptor  and   
ligand  expression  was  found  largely  in   
the  suprabasal  cells,  and  in  vitro  data   
suggested that Notch activation induces   
differentiation  and  cell  cycle  arrest 
(Lowell et al., 2000; Rangarajan et al., 
2001;  Nguyen  et  al.,  2006).  Condi­
tional  deletion  of  NOTCH1  in  the   
skin resulted in a significant increase of   
the basal epidermal layer (Rangarajan   
et al., 2001). Consistent with a tumor­
suppressive function for Notch in the 
skin,  NOTCH1  loss  of  function  re­
sulted in spontaneous basal cell carcino­
mas that appeared in older mice and 
sensitization to chemically induced skin 
carcinogenesis  (Nicolas  et  al.,  2003). 
This  work  also  suggested  that  Notch 
acts as a tumor suppressor in the skin 
through  suppression  of  the  Wnt  and 
Sonic–hedgehog pathways. A subsequent 
study indicated that the tumorigenic ef­
fect of Notch1 deletion is the result of a 
non–cell  autonomous  defect  in  the 
integrity of the skin barrier (Demehri 
and Kopan, 2009). Thus, mechanistically, 
tumor inhibition in the skin may involve 
feedback with the microenvironment in 
addition to cross talk between Notch and 
other signaling pathways.
In this issue of the Journal of Experi-
mental  Medicine,  Viatour  et  al.  (2011) 
propose a novel tumor suppressor role 
for  Notch  signaling  in  hepatocellular 
carcinoma (HCC). HCC is one of the 
most devastating cancers, with >600,000 
deaths/yr  worldwide,  and  is  strongly   
associated with prior hepatitis virus B   
or C infection. To gain further insights 
into  the  mechanism  driving  initiation 
and  progression  of  HCC,  the  authors 
generated a mouse model of the disease 
by deleting the retinoblastoma protein 
(RB) and its two related family mem­
bers  p107  and  p130  in  mouse  liver. 
These  triple  KO  (TKO)  mice  devel­
oped liver cancer with histological and 
molecular  features  typical  of  human 
HCC. In their model, inactivation of 
the RB pathway led to the expansion of 
the  stem/progenitor  compartment  in 
the liver. The authors propose that these 
(Ranganathan et al., 2011). The onco­
genic  potential  of  Notch  activation  in 
solid  tumors  was  first  observed  in   
mouse mammary tumor virus (MMTV)– 
driven  breast  cancer.  The  integration   
of MMTV in specific loci of the host 
genome  resulted  in  dysregulated  ex­
pression of adjacent genes and subse­
quent outgrowth of tumorigenic clones. 
Characterization  of  one  of  these  loci   
revealed expression of a truncated con­
stitutively active form of Notch4 (Gallahan 
et  al.,  1987).  In  mouse  models,  Notch   
activation  can  clearly  drive  mammary   
tumors,  and  in  human  breast  cancer,   
increased  expression  of  Notch  or  Jag1 
correlates with poor prognosis (Reedijk 
et  al.,  2005).  However,  few  activating 
mutations  of  the  Notch  pathway  have 
been found in solid tumor patients, with 
most being observed in NSCLC (Westhoff 
et al., 2009).
Two  recent  studies  have  identi­
fied activating NOTCH1 mutations in 
chronic lymphocytic leukemia (CLL), 
a frequent adult leukemia (Fabbri et al.,   
2011; Puente et al., 2011). CLL is char­
acterized by variable clinical presenta­
tion and progression but can be divided 
into two major subtypes: one with mu­
tated immunoglobulin genes (IGV(H)),   
and another more aggressive form with 
nonmutated IGV(H) . Both studies iden­
tified  NOTCH1­activating  mutations 
(mainly a frame shift mutation at codon   
2515) predicted to impair Fbw7­induced   
Notch1  degradation.  Although  the 
overall  frequency  was  not  dramatic 
(from 8.3 to 12.2%), these NOTCH1 
mutations were primarily found in pa­
tients with the more clinically aggres­
sive nonmutated IGV(H) subtype of CLL 
(20.4%) in Richter syndrome (31.0%), 
and in chemorefractory CLL (20.8%). 
These  results  suggest  that  although 
NOTCH1  mutations  are  not  patho­
gnomonic or causative of CLL, they are   
associated with poor prognosis and could 
define a distinct clinical subtype for ther­
apeutic intervention.
Notch as a tumor suppressor
Although Notch activation (especially 
at higher levels as conferred by ICN1 
expression) can be oncogenic, there is 
growing evidence that components of embryonic development and in adult tis­
sues,  it  is  perhaps  not  surprising  that   
aberrant Notch signaling can result in a   
wide range of pathological consequences. 
The  oncogenic  function  of  Notch  in 
lymphocytes and mammary tissue, versus 
the growth­suppressive role in HCC, 
CMML, HNSCC, and skin, highlights 
the intriguing dual role of a single sig­
naling pathway (see Table I for a listing 
of  Notch  function  in  selected  cancer 
types). Indeed, depending on the cel­
lular context, Notch may promote stem 
cell maintenance or induce terminal 
differentiation.
The  detailed  mechanistic  expla­
nation of this duality of action remains 
under  investigation. We  propose  that   
in  both  cases  (oncogenic  and  tumor 
suppressive function), Notch signaling   
mainly targets programs of stem and pro­
genitor  cell  differentiation,  acting  as  a   
cell fate determinant. By affecting nor­
mal differentiation, Notch could set the 
stage for additional mutations and even­
tual cell transformation. For example, in 
myeloid leukemia, defective Notch sig­
naling (caused either by mutations or by 
domain  of  the  Notch  receptors  and 
therefore predicted to be loss­of­function 
mutations.  The  significance  of  these 
mutations in HNSCC requires further 
validation;  nevertheless,  they  impli­
cate NOTCH1 as a tumor suppressor   
in HNSCC.
Finally, in B cell malignancies, Notch 
was also reported to suppress growth and 
induce  apoptosis,  providing  additional 
evidence  that  Notch  could  act  as  a   
tumor suppressor in hematopoietic cells 
(Zweidler­McKay et al., 2005). Another 
recent study suggested a similar tumor 
suppressor  role  for  Notch  signaling  in 
neuroblastoma (Zage et al., 2011). How­
ever these data were mostly generated 
from in vitro studies using enforced 
overexpression of ICN1 or stimulation 
with recombinant Notch ligand and will 
require further in vivo validation. It will 
thus  be  important  to  test  the  role  of 
Notch in these disease models using in 
vivo genetic approaches.
Conclusion/future directions
Given that Notch is involved in an array 
of fundamental processes both during 
the tumor­suppressive function of Notch 
in epithelial cells and HCC, these stud­
ies suggested that Notch signaling may 
also act to prevent uncontrolled prolif­
eration and transformation of  myeloid 
cells during hematopoietic development.
Furthermore, two recent studies of 
head and neck squamous cell carcinoma 
(HNSCC),  the  sixth  most  common 
cancer worldwide, identified mutations 
affecting Notch receptors. Agrawal et al. 
(2011) identified 28 different NOTCH1 
mutations in 21/120 patients (17.5%). 
11 of these mutations were nonsense or 
insertion/deletions  predicted  to  result 
in loss of function, supporting a tumor­
suppressive  function  for  Notch  in   
HNSCC. The remaining 17 were mis­
sense mutations, mostly within the extra­
cellular EGF­like repeats that are required 
for receptor–ligand interaction. A study 
by  Stransky  et  al.  (2011)  identified 
NOTCH1 mutations in 11% of patients 
analyzed  and  NOTCH2  or  NOTCH3 
mutations in an additional 11% of pa­
tients. Mutations identified in this study 
were nonsense, missense, or insertion/ 
deletions  targeting  the  extracellular 
Table I.  Dual role of Notch signaling in cancer
Tumor type Role of Notch signaling Genes mutated Putative or observed effect References
T-ALL Oncogene NOTCH1 
FBXW7
Ligand independent activation 
Stabilization of N1-IC
Ellisen et al., 1991 
Weng et al., 2004 
Malyukova et al., 2007 
Maser et al., 2007 
O’Neil et al., 2007 
Thompson et al., 2007
CLL Oncogene NOTCH1 Stabilization of N1-IC 
Correlated with reduced survival
Fabbri et al., 2011 
Puente et al., 2011
NSCLC Oncogene NOTCH1 Stabilization of N1-IC 
Correlated with reduced survival
Westhoff et al., 2009
PDAC Oncogene 
Tumor suppressor
none Loss of NOTCH1 decreased tumor latency 
Loss of NOTCH2 increased tumor latency
Hanlon et al., 2010 
Mazur et al., 2010
HCC Tumor suppressor none Endogenous activation of Notch induces growth arrest and 
apoptosis 
Activated Notch pathway correlated with better survival
Viatour et al., 2011
CMML Tumor suppressor NCSTN 
MAML1 
APH1A 
NOTCH2
Loss of function mutations 
Activated Notch signaling inhibits myeloid progenitor 
differentiation.
Klinakis et al., 2011
HNSCC Tumor suppressor NOTCH1 
NOTCH2 
NOTCH3
Truncated or ligand-binding inefficient receptors 
Predicted to impair differentiation
Stransky et al., 2011 
Agrawal et al., 2011
B-ALL Tumor suppressor none Endogenous or exogenous activation of Notch induces 
growth arrest and apoptosis
Zweidler-McKay et al., 2005
PDAC: pancreatic ductal adenocarcinoma; B-ALL: B cell acute lymphoblastic leukemia.
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initiating  population,  and  not  before 
their commitment.
Further detailed studies are required 
to integrate such hypotheses, including 
a  detailed  analysis  of  Notch  receptor 
interactions  with  ligands  in  specialized 
tissue  microenvironments.  Moreover, 
with growing interest in clinical applica­
tions of ­secretase inhibitors (GSIs) and 
blocking  antibodies  to  Notch  ligands, 
it is vital to understand all possible sys­
temic  consequences  of  Notch/RBP­J 
inhibition (Real et al., 2009). Whereas 
inhibition  of  Notch  may  have  clinical 
efficacy where Notch has an oncogenic 
role, activation of Notch using peptides 
or antibodies should be evaluated as a 
therapeutic target in malignancies where 
NOTCH plays a tumor­suppressive role.
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